News

Role of Siponimod in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

Treating With Cladribine in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

Clinical Trials for Cladribine in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

The Use of Glatiramer Acetate in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

The Use of Interferon in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

First-Line Therapies for Relapsing Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

Clinically Isolated Syndrome Versus Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

MOG-IgG in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

Differential Diagnosis of Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

Diagnosis of Multiple Sclerosis: The McDonald Criteria

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD

AMX0035 Slows Functional Decline in ALS in Phase 2/3

Mary Schroth, MD: The Impact of FDA Approvals on SMA Advocacy

Data from the CENTAUR trial showed that the monthly rate of decline measured by ALSFR-S was 0.42 points slower for patients treated with the combination agent AMX0035.

Mary Schroth, MD, FAAP, FCCP

Longitudinal Sleep Problems in Children Linked With Negative Well-Being

The chief medical officer at Cure SMA detailed the importance of having various treatment options for patients, particularly for adults with SMA.

Lacosamide Reduces Risk of Second Tonic-Clonic Seizure

The findings support the integration of sleep assessments into routine developmental screenings in school and primary care settings.

Modified Atkins and Low Glycemic Index Diets Noninferior to Ketogenic Diet in Epilepsy

The FDA-approved epilepsy monotherapy showed significant reductions in primary generalized tonic-clonic seizures of ≥50% and ≥75% from baseline.

Solriamfetol Improves Excessive Daytime Sleepiness and Driving Performance Ability

A low glycemic index therapy diet is associated with the least number of and least severe adverse events among all 3 epileptic diet methods, with similar reductions in seizure burden.

Pitolisant Improves Daytime Sleepiness and Cataplexy in Severely Burdened Patients

The FDA-approved agent showed significant impact in decreasing standard deviation of lateral position, a measure used to assess driving performance.

Marwan Sabbagh, MD: Observations From AAIC 2020

Pooled data from 2 clinical trials of the H3-receptor antagonist/inverse agonist show it improved cataplexy and excessive daytime sleepiness in patients with narcolepsy who were most hampered by symptoms.

Marwan Sabbagh, MD

AUPN Leading Edge Episode 2: So You Want to Be a Dean? Pros, Cons, Joys and Tribulations

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic detailed the state of Alzheimer disease and what research particularly grabbed his attention at AAIC 2020.

Clifton L. Gooch, MD;Charles Lockwood, MD

Lemborexant Demonstrates Efficacy in Elders

Podcast

AUPN Leading Edge Episode 2 features Clifton Gooch, MD, and Charles Lockwood, MD, who explore making the leap from chair to dean. [LISTEN TIME: 25 minutes]

Mary Schroth, MD: Making Strides in Treating Spinal Muscular Atrophy

Already FDA approved for the treatment of insomnia in adults, lemborexant’s ability to improve sleep outcomes in the elderly was highlighted in a study presented at SLEEP 2020.

Mary Schroth, MD, FAAP, FCCP

August 31st 2020

The Key Role of Biomarkers in Alzheimer Disease Research

The chief medical officer at Cure SMA offers insight on the current SMA therapeutic landscape and what the organization is focused on going forward.

August 31st 2020

Cala Trio Neuromodulation Device Effectively Reduces Symptoms in Essential Tremor

In part 2 of this interview, Marwan Sabbagh, MD, provides insight on what he feels is the most promising field of research in Alzheimer disease right now.

August 31st 2020

Selective Inverse Agonists of the Histamine 3 Receptor as Treatment for Narcolepsy

After wearing the noninvasive device, 62% of TETRAS-rated patients and 68% of BF-ADL-rated patients whose tremors were rated as "severe" or "moderate" improved to "mild" or "slight" scores.

Jennifer S. Sun, PhD

August 29th 2020

Lara Jehi, MD: Evidence Abounds for the Benefits of Epilepsy Surgery

Managing narcolepsy via behavioral strategies to improve excessive daytime sleepiness may be challenging but has shown some added efficacy when combined with pharmacological treatment for EDS.

Lara Jehi, MD

August 29th 2020

Closing the Treatment Gap in Progressive MS

The chief research officer and epilepsy specialist at Cleveland Clinic detailed how recent study findings might impact the patient perspective on epilepsy surgery.

Tori Rodriguez, MA

August 29th 2020